Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).  Its experienced and dedicated team is committed to making a difference in the lives of patients and their families.  Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.  REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.

Drug Pipeline

Powered by